科学图书馆
-
A trial to evaluate the effect of the sodium-glucose co-transporter 2 inhibitor dapagliflozin on morbidity and mortality in patients with heart failure and reduced left ventricular ejection fraction (DAPA-HF)McMurray JJV, DeMets DL, DAPA-HF Committees and Investigators. -
Universal Definition and Classification of Heart Failure: A Report of the Heart Failure Society of America, Heart Failure Association of the European Society of Cardiology, Japanese Heart Failure Society and Writing Committee of the Universal Definition of Heart FailureB Bozkurt, AJS Coats, H Tsutsui et al.
-
Association of Cardiovascular Disease With Respiratory DiseaseP Carter, J Lagan, C Fortune et al.
-
The Role of the Pericardium in Heart Failure: Implications for Pathophysiology and TreatmentBA Borlaug, YNV Reddy.
-
Angiotensin–Neprilysin Inhibition in Heart Failure with Preserved Ejection FractionSD Solomon, the PARAGON-HF Investigators and Committees. JohnJV McMurray,
-
Haemodynamic-guided management of heart failure (GUIDE-HF): a randomised controlled trialJA Lindenfeld, MR Zile, AS Desai et al.
-
Empagliflozin Increases Cardiac Energy Production in Diabetes - Novel Translational Insights Into the Heart Failure Benefits of SGLT2 InhibitorsS Verma, S Rawat, KL Ho et al.
-
The prevalence and importance of frailty in heart failure with reduced ejection fraction - an analysis of PARADIGM-HF and ATMOSPHEREDewan P, Jackson A, Jhund PS et al.
http://www.cbsmd.cn Contact us by cbs@cbsmd.cn
Copyright ⓒ CBSMD Nanjing China. All rights reserved.
